AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15130462 — intervention group
Group type: EXPERIMENTAL
Intervention: Early imaging
Number of subjects: 782
Study 15130462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early imaging)
Number of subjects: 782
Study 11936570 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 11936570 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 9718191 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-B irradiation at half the minimal erythemal dose of the lower back, three times per week during 12 weeks
Number of subjects: 45
Study 9718191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 400 IU/day during 12 weeks
Number of subjects: 45
Study 9718191 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study 7651075 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized all‐trans beta‐carotene (60 mg daily)
Number of subjects: 30
Study 7651075 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally‐occurring beta‐carotene derived from Dunaliella bardawil
Number of subjects: 30
Study 7651075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2717353 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand Group (exaggerated facial expressions)
Number of subjects: 56
Study 2717353 — intervention group
Group type: EXPERIMENTAL
Intervention: Contradictory Expression Group (contradictory facial expressions)
Number of subjects: 56
Study 2717353 — intervention group
Group type: COMPARATOR
Intervention: Nondemand Group (no instructions about facial expressions)
Number of subjects: 56
Study 393047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 20
Study 393047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30897297 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic absorbable polyglactin (Vicryl®) mesh reinforcement
Number of subjects: 69
Study 30897297 — intervention group
Group type: COMPARATOR
Intervention: No mesh reinforcement (control group)
Number of subjects: 69
Study 31425930 — intervention group
Group type: EXPERIMENTAL
Intervention: Past-year opioid misuse
Number of subjects: 130
Study 31425930 — intervention group
Group type: COMPARATOR
Intervention: Other substances or alcohol use
Number of subjects: 130
Study 28012026 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA (Arachidonic acid)
Number of subjects: 3
Study 28012026 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA + ASA (Acetylsalicylic acid)
Number of subjects: 3
Study 28012026 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA
Number of subjects: 3
Study 28012026 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA + ASA
Number of subjects: 3
Study 28012026 — intervention group
Group type: COMPARATOR
Intervention: ARA-free (control)
Number of subjects: 3
Study 25409110 — intervention group
Group type: EXPERIMENTAL
Intervention: Home DLMOs
Number of subjects: 35
Study 25409110 — intervention group
Group type: COMPARATOR
Intervention: Laboratory DLMOs
Number of subjects: 35
Study 23611079 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 31
Study 23611079 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 31
Study 21942184 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation
Number of subjects: 120
Study 21942184 — intervention group
Group type: COMPARATOR
Intervention: Medication (Tramadol Hydrochloride Capsules 100 mg)
Number of subjects: 120
Study 19826294 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with shoes at 2 mm amplitude
Number of subjects: 10
Study 19826294 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) without shoes at 2 mm amplitude
Number of subjects: 10
Study 19826294 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with shoes at 4 mm amplitude
Number of subjects: 10
Study 19826294 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) without shoes at 4 mm amplitude
Number of subjects: 10
Study 19826294 — intervention group
Group type: COMPARATOR
Intervention: Unloaded isometric half squat (without WBV)
Number of subjects: 10
Study 17108815 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 344
Study 17561541 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP therapy
Number of subjects: 1100
Study 17561541 — intervention group
Group type: COMPARATOR
Intervention: Sham (subtherapeutic) CPAP
Number of subjects: 1100
Study 14717308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine lignocaine
Number of subjects: 53
Study 14717308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 10389123 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac plus 0.3% tobramycin
Number of subjects: 10
Study 10389123 — intervention group
Group type: COMPARATOR
Intervention: Voltaren (diclofenac sodium)
Number of subjects: 10
Study 10389123 — intervention group
Group type: COMPARATOR
Intervention: Physiological Saline Braun
Number of subjects: 10
Study 10389123 — intervention group
Group type: COMPARATOR
Intervention: Tobrex (tobramycin sulfate)
Number of subjects: 10
Study 10389123 — intervention group
Group type: COMPARATOR
Intervention: Control 0.3% tobramycin solution
Number of subjects: 10
Study 9049706 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost treatment
Number of subjects: 8
Study 9049706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1725068 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MU (= 10.4 mg) BM 06.022
Number of subjects: 7
Study 1725068 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 7
Study 6847852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose, 50 g as a 10% solution
Number of subjects: 16
Study 6847852 — intervention group
Group type: COMPARATOR
Intervention: Sucrose, 50 g as a 10% solution
Number of subjects: 16
Study 31959167 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 μg
Number of subjects: 51
Study 31959167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30107437 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation (DE)
Number of subjects: 150
Study 30107437 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SU ⩾ 8 mg/dl
Number of subjects: 150
Study 28557902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved amniotic (cAM) tissue
Number of subjects: 80
Study 28557902 — intervention group
Group type: COMPARATOR
Intervention: No tissue (control)
Number of subjects: 80
Study 25920338 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental rotational grade V manipulation (manipulation)
Number of subjects: 50
Study 25920338 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated lumbar extension in lying exercise (EIL)
Number of subjects: 50
Study 24139772 — intervention group
Group type: EXPERIMENTAL
Intervention: Park-director intervention (PD-only)
Number of subjects: 50
Study 24139772 — intervention group
Group type: EXPERIMENTAL
Intervention: PAB intervention (PAB/PD)
Number of subjects: 50
Study 24139772 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 50
Study 21047544 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 31
Study 21047544 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 31
Study 21047544 — intervention group
Group type: COMPARATOR
Intervention: Perospirone
Number of subjects: 31
Study 18261680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 310
Study 18261680 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 310
Study 16749570 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure pneumoperitoneum (12‐14mmHg)
Number of subjects: 20
Study 16749570 — intervention group
Group type: COMPARATOR
Intervention: Low pressure pneumoperitoneum (6‐8mmHg)
Number of subjects: 20
Study 15222589 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of alcohol (0.34 g/kg women; 0.4 g/kg men)
Number of subjects: 68
Study 15222589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 11142528 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg)
Number of subjects: 29133
Study 11142528 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg)
Number of subjects: 29133
Study 11142528 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29133
Study 9451581 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic injections of adrenergic antagonist L657,743
Number of subjects: 0
Study 9451581 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 9451581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed modality oddball paradigm with auditory context
Number of subjects: 0
Study 9451581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed modality oddball paradigm with visual context
Number of subjects: 0
Study 8395716 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH prophylaxis once a day
Number of subjects: 253
Study 8395716 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 253
Study 2943195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.i.d.)
Number of subjects: 58
Study 2943195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31923367 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric Hypoxia (NH)
Number of subjects: 8
Study 29929055 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hour afternoon nap
Number of subjects: 39
Study 29929055 — intervention group
Group type: COMPARATOR
Intervention: No nap (control group)
Number of subjects: 39
Study 27786516 — intervention group
Group type: EXPERIMENTAL
Intervention: mPE
Number of subjects: 126
Study 27786516 — intervention group
Group type: EXPERIMENTAL
Intervention: mPE + MET-PTSD
Number of subjects: 126
Study 27786516 — intervention group
Group type: COMPARATOR
Intervention: HLS (control)
Number of subjects: 126
Study 27786516 — intervention group
Group type: EXPERIMENTAL
Intervention: mPE and mPE + MET-PTSD
Number of subjects: 126
Study 27786516 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 126
Study 25050591 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg infused at Weeks 0, 2, 6, 14, and 22, with escalation to 5 or 7 mg/kg based on EULAR response at Weeks 14 and 22.
Number of subjects: 203
Study 25050591 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg with dose escalation based on EULAR response.
Number of subjects: 203
Study 25050591 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment with dose escalation.
Number of subjects: 203
Study 22575081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education videoconferences
Number of subjects: 60
Study 22575081 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 60
Study 20829151 — intervention group
Group type: EXPERIMENTAL
Intervention: Composites filled with nanoparticles
Number of subjects: 41
Study 20829151 — intervention group
Group type: COMPARATOR
Intervention: Microhybrid composite
Number of subjects: 41
Study 18372037 — intervention group
Group type: EXPERIMENTAL
Intervention: Empress II crowns
Number of subjects: 36
Study 18372037 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional metal‐ceramic crowns
Number of subjects: 36
Study 18372037 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-ceramic crowns with framework ending 2mm coronal to the axiogingival line angle
Number of subjects: 36
Study 18372037 — intervention group
Group type: EXPERIMENTAL
Intervention: Try-in pastes used in all test groups
Number of subjects: 36
Study 15948536 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program on sun exposure
Number of subjects: 1945
Study 15948536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 1945
Study 12654955 — intervention group
Group type: EXPERIMENTAL
Intervention: CR oxycodone (10 mg tablet every 12 hours, max 60 mg every 12 hours)
Number of subjects: 159
Study 12654955 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablet every 12 hours)
Number of subjects: 159
Study 12654955 — intervention group
Group type: EXPERIMENTAL
Intervention: CR oxycodone
Number of subjects: 159
Study 12654955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 11189670 — intervention group
Group type: EXPERIMENTAL
Intervention: Control + pain booklet
Number of subjects: 45
Study 11189670 — intervention group
Group type: EXPERIMENTAL
Intervention: Control + pain booklet and interview
Number of subjects: 45
Study 11189670 — intervention group
Group type: COMPARATOR
Intervention: Generic hospital booklet and videotape (control)
Number of subjects: 45
Study 8857383 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-factor model indicating 'general dependence' and 'failed cessation' dimension
Number of subjects: 394
Study 1726003 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of lacidipine once daily (n = 220)
Number of subjects: 435
Study 1726003 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of nifedipine SR twice daily (n = 215)
Number of subjects: 435
Study 1726003 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of lacidipine once daily (n = 82)
Number of subjects: 435
Study 1726003 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of nifedipine SR twice daily (n = 62)
Number of subjects: 435
Study 1726003 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of atenolol once daily (n = 32)
Number of subjects: 435
Study 1726003 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of atenolol once daily (n = 23)
Number of subjects: 435
Study 6486846 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid (HC) occlusive dressing (DuoDerm)
Number of subjects: 22
Study 6486846 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid (HC) dressing
Number of subjects: 22
Study 6486846 — intervention group
Group type: COMPARATOR
Intervention: Mild topical antimicrobial wet dressings (Sweitzer's 1:32 solution)
Number of subjects: 22
Study 31517967 — intervention group
Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 866
Study 31517967 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural mentoring
Number of subjects: 866
Study 30371329 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 30
Study 26758677 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 106
Study 26758677 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 106
Study 25128594 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical loteprednol etabonate and eyelid scrubs with warm compresses (Group I)
Number of subjects: 70
Study 25128594 — intervention group
Group type: COMPARATOR
Intervention: Eyelid scrubs with warm compresses alone (Group II)
Number of subjects: 70
Study 22669848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (Macugen® 0.3 mg = 0.02 mL) combined with conventional diode laser photocoagulation in group 1 (68 eyes of 34 infants)
Number of subjects: 152
Study 22669848 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser therapy combined with cryotherapy in group 2 (84 eyes of 42 infants)
Number of subjects: 152
Study 21182350 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r)
Number of subjects: 0
Study 21182350 — intervention group
Group type: COMPARATOR
Intervention: Control PI-based HAART
Number of subjects: 0
Study 18353886 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (300 eccentric-concentric actions)
Number of subjects: 7
Study 18353886 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (300 concentric actions)
Number of subjects: 7
Study 16195124 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time milk containing 10-40 ng/l melatonin, consumed daily for 8 weeks.
Number of subjects: 151
Study 16195124 — intervention group
Group type: COMPARATOR
Intervention: Normal daytime milk, consumed as a control for 8 weeks.
Number of subjects: 151
Study 16195124 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time milk consumed during the first period of the crossover study.
Number of subjects: 151
Study 16195124 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time milk consumed during the later period of the crossover study.
Number of subjects: 151
Study 16195124 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time milk consumed during winter solstice.
Number of subjects: 151
Study 12869401 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized reading of paired films from individuals one after the other (random and unknown order)
Number of subjects: 404
Study 12869401 — intervention group
Group type: COMPARATOR
Intervention: Randomized reading of all films
Number of subjects: 404
Study 12869401 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects randomized, sequential order known to the reader
Number of subjects: 404
Study 12869401 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects randomized, random order unknown to the reader, simultaneous reading on separate screens
Number of subjects: 404
Study 10887919 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 40
Study 10887919 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg) and Alfentanil (10 microg/kg)
Number of subjects: 40
Study 10887919 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 40
Study 10887919 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg) and Vecuronium (0.1 mg/kg)
Number of subjects: 40
Study 8629746 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC‐201 (45 g)
Number of subjects: 24
Study 8629746 — intervention group
Group type: COMPARATOR
Intervention: Control solution (Ringer's lactate)
Number of subjects: 24
Study 1593511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 96
Study 1593511 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking
Number of subjects: 96
Study 1593511 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 96
Study 1593511 — intervention group
Group type: COMPARATOR
Intervention: Neutral reading
Number of subjects: 96
Study 3905222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac 50 mg 3 times daily
Number of subjects: 60
Study 3905222 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumethacin 150 mg 3 times daily
Number of subjects: 60
Study 3905222 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 60
Study 29982939 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PRF used in addition to another layer
Number of subjects: 40
Study 29982939 — intervention group
Group type: COMPARATOR
Intervention: Traditional graft materials (control group)
Number of subjects: 40
Study 29982939 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PRF
Number of subjects: 40
Study 26435033 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin initiation with glargine, with or without glulisine
Number of subjects: 89
Study 24773163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonharmful drinkers
Number of subjects: 3538
Study 24773163 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmful/likely dependent drinkers
Number of subjects: 3538
Study 24773163 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing a dose of HIV medications
Number of subjects: 3538
Study 24773163 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent condom use
Number of subjects: 3538
Study 24773163 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchanging sex for food, money, gifts, or a place to stay
Number of subjects: 3538
Study 24773163 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a sexually transmitted infection symptom
Number of subjects: 3538
Study 23134888 — intervention group
Group type: EXPERIMENTAL
Intervention: HSF-DHA diet (3.45 g DHA/d)
Number of subjects: 88
Study 23134888 — intervention group
Group type: EXPERIMENTAL
Intervention: HSF diet
Number of subjects: 88
Study 20130968 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg rise (PLR1)
Number of subjects: 40
Study 20130968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid loading (FL)
Number of subjects: 40
Study 20130968 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg rise (PLR2) after fluid loading
Number of subjects: 40
Study 20130968 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg rise (PLR1) in non-responders (NR)
Number of subjects: 40
Study 19195454 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg once daily)
Number of subjects: 0
Study 19195454 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (once or twice daily)
Number of subjects: 0
Study 19195454 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 0
Study 16115248 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural beat audio
Number of subjects: 0
Study 16115248 — intervention group
Group type: COMPARATOR
Intervention: Audio Group (identical soundtrack without binaural beats)
Number of subjects: 0
Study 16115248 — intervention group
Group type: COMPARATOR
Intervention: No Intervention Group
Number of subjects: 0
Study 12215586 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsies analyzed by electron microscopy
Number of subjects: 21
Study 12215586 — intervention group
Group type: EXPERIMENTAL
Intervention: COL3A1 gene analysis
Number of subjects: 21
Study 12072853 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made biomechanic shoe orthoses
Number of subjects: 146
Study 9805325 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 0
Study 9805325 — intervention group
Group type: COMPARATOR
Intervention: Normal elderly
Number of subjects: 0
Study 9805325 — intervention group
Group type: COMPARATOR
Intervention: Normal young
Number of subjects: 0
Study 9805325 — intervention group
Group type: EXPERIMENTAL
Intervention: Young normal participants with concurrent memory load
Number of subjects: 0